PAHdb (http://www.mcgill.ca/pahdb ) is a curated relational database (Fig. 1 ) of nucleotide variation in the human PAH cDNA (GenBank U49897). Among 328 different mutations by state (Fig. 2 ) the majority are rare mutations causing hyperphenylalaninemia (HPA) (OMIM 261600), the remainder are polymorphic variants without apparent effect on phenotype. PAHdb modules contain mutations, polymorphic haplotypes, genotypephenotype correlations, expression analysis, sources of information and the reference sequence; the database also contains pages of clinical information and data on three ENU mouse orthologues of human HPA. Only six different mutations account for 60% of human HPA chromosomes worldwide, mutations stratify by population and geographic region, and the Oriental and Caucasian mutation sets are different (Fig. 3) . PAHdb provides curated electronic publication and one third of its incoming reports are direct submissions. Each different mutation receives a systematic (nucleotide) name and a unique identifier (UID). Data are accessed both by a Newsletter and a search engine on the website; integrity of the database is ensured by keeping the curated template offline. There have been >6500 online interrogations of the website.
Genetics is the study of heredity, biological variation and the mechanisms thereof. Genomics is the study of genomes and the genes they harbour. Medicine is the science (and art) of health maintenance and disease cure, alleviation and prevention. An abiding hope (and belief) is that the Human Genome Project will bring about a great instauration of 'genetic medicine', where genetic and medical thinking are fused. But in the abundance of information emerging in genetics and genomics and from the technologies they have spawned there arises a concern that the attendant knowledge could be obscured by the sheer mass of information. How then to record the essential information about variation in DNA, about mutations both disease-causing and neutral, and have it available to translate into genetic and medical knowledge? This is a goal of mutation databases to which the Human Genome Organization (HUGO) is committed (1) .
THE PAH MUTATION DATABASE (http://www.mcgill.ca/pahdb)
This relatively large relational database (PAHdb) documents variation (mutations) in nucleotide sequence of the human cDNA for the phenylalanine hydroxylase gene [symbol PAH; GenBank U49897. Mutation numbering from the PAHdb annotated sequence begins with the A of ATG (codon 1) 473 nt into the cDNA sequence; nucleotide numbering in U49897 begins with the first 5′ base. NCBI has software to find the ATG codon and adjust numbering for nomenclature purposes.] and its enzyme (SWISS-PROT P00439); PAHdb records variation both disease-causing (notably those causing phenylketonuria, OMIM 261600) and neutral (polymorphic). PAHdb has been built as a prototype for other locusspecific mutation databases that will serve genetic medicine; it is already linked to centralized human genetic databases such as Human Genome Mutation Database (HGMD) (2) (http://www.cf.ac.uk/uwcm/mg/hgmd0.html ); and Online Mendelian Inheritance in Man (OMIM) (http://www.ncbi.nlm.nih.gov/ Omim ). It could also be linked to interorganismal databases such as XREF (3) . This, the third in a series of reports (4, 5) , describes continuing growth, use and relevance of PAHdb.
THE DATABASE: STRUCTURE, DEVELOPMENT AND MAINTENANCE
PAHdb has in excess of 4000 records in >60 data tables distributed in conceptual modules (Fig. 1 ). An overview of the design is the purpose of this section.
Documentation
A mutation database is a record of discovery and intellectual property and at the moment, the pace of mutation discovery far exceeds the capacity to publish the data by conventional means; an alternative is electronic publication, now in databases, eventually in journals. Peer review is always required, hence PAHdb is curated (edited) and under constant scrutiny by its *To whom correspondence should be addressed. Tel: +1 514 934 4417; Fax: +1 514 934 4329; Email: mc77@musica.mcgill.ca Consortium members (and users). Curators will come and go; hence the database must be documented for continuity; meaning, its conceptual and physical design will always have a formal (evolving) record describing the flow of data, with instructions to users of its interfaces. The Document will be deposited as part of a thesis by one of us (PMN).
Design
Modules form the structure of PAHdb (Fig. 1) . Each locus-specific mutation database will have a particular design and content but some degree of standardization is desirable if they are to be linked to centralized repositories and information is to be shared. Elsewhere we have proposed a way to achieve consensus through agreement on types of information (6) . Primary information is standardized. It describes the mutation in biological terms using a sequence-based nomenclature. For example, the human M1V mutation in PAH (7) has three contexts: the human genome, a gene name and an accession number (GenBank) for the nucleotide sequence; thus: HSAP:PAH:U49897::M1V. Whereas the M1V mutation was initially reported by its trivial name it also has a systematic mutation name (c.1A→G, where 1 is the mutated nucleotide, A→G is the mutation, and c. refers to cDNA, the source of the annotated PAH sequence in the database); see S.E.Antonarakis at http://www.bio.net/hypermail/MUTATION/ 9705/0007.html for guidelines on mutation nomenclature. Accordingly, information on the M1V mutation is fully conveyed by: HSAP:PAH:U49897::c.1A→G; the trivial name (M1V) is a useful but not a necessary convention.
Secondary information covers attributes and descriptors of the mutation. For example, the association of the M1V mutation with its polymorphic haplotype background and the population and geographic region in which it is found; M1V was originally reported on PAH haplotype 2 and it occurs in Quebec (French Canadians) and France (French). The additional attributes and descriptors of a mutation are edited and listed in PAHdb. Tertiary information is that which is curatorial in nature, including the edit histories and comments; they are part of the record and include unique identifiers for the mutations. Under ideal conditions, patient (sample) identifiers would have been assigned to trace alleles (chromosomes).
Software
PAHdb currently uses Visual FoxPro 5.0 as its database management system (DBMS) and VFP, an object-oriented derivative of the original X-Base language, for programming and development.
Search engine
An offline copy of PAHdb is continuously edited and updated by the curators; edited copies are deposited at intervals on the server (http://www.mcgill.ca/pahdb ) where it can be used. A search engine (West Wind Web Connection http://www.west-wind.com ) gives Web users the opportunity to interrogate the database. Integrity is ensured because the original (edited) template is offline.
THE DATABASE: CONTENT AND UTILIZATION

Nomenclature and identity
Whereas the visual summary of PAH mutations (Fig. 2) uses their trivial names (8) , the database and Newsletter provide the systematic (nucleotide) names, keyed to the 'Konecki' cDNA sequence (9) . Unique identifiers (UIDs) have been given to each PAH mutation different by state.
Since PAHdb is a relational database it requires records to be linked on unique keys to keep tables properly related, and to avoid dangling tuples, as well as insertion and deletion anomalies. Use of the trivial mutation name alone is insufficient; for example, there could have been loss of data when the Y204C 'missense' mutation name was changed to the systematic name E6nt-96A→g recognizing that it is actually a splice mutation (10) . Earlier versions of the DBMS (FoxPro 2.x) did not automatically enforce referential integrity but that difficulty has been overcome in Visual FoxPro and enhanced by the use of UIDs. On the other hand, the current system does not yet assign different UIDs to recurrent mutations (for example, R408W has one UID, number 121, but two origins in recurrent mutation) (11) .
Alleles, chromosomes and UIDs
PAHdb records 12 279 'alleles'. To use the alternative term, 'chromosome', implies the source of the DNA sequence harbouring the mutation; a feature that should merit an identifier for each chromosome and the person of origin. PAHdb has not been able to take this step. Here, we use the term 'allele' mainly to implicate the possibility of different background nucleotide sequences in the PAH gene. We know that mutations identical by state can be different alleles; recurrent mutations are different alleles (e.g. R408W) (11) . As knowledge emerges about the haplotypes harbouring mutations, and ultimately about the full genomic PAH sequences harbouring them, it should be possible to describe the relative degree of uniqueness of mutations.
There is a practical short-term problem: The record of 12 279 'alleles' is clearly not a record of that many independent chromosomes. The database uses reports, both published and submitted (see module). However a cumulative record for a given region or population does not obliterate the earlier (partial) reports. In the absence of assigning a UID for each chromosome (allele) at the initial report, PAHdb cannot document the actual number of independent alleles in the database. We had to deal with this deficiency in database design when calculating relative population frequencies of particular mutations (see below).
Mutations
On September 10, 1997 there were 328 different mutations (by state) in PAHdb; their distribution in the gene is shown in Figure 2 . Since they were ascertained in probands with hyperphenylalaninemia (HPA), by definition those due to deficient phenylalanine hydroxylase function (12) , the majority of these mutations are likely to be 'disease-causing', but not necessarily so. Although some are apparently neutral polymorphisms, notably the 'silent' mutations in codons and mutations deep in introns, it is too early to say categorically that all PAH polymorphisms are without any effect on PAH gene function.
PAHdb also classifies mutations by type (Fig. 2, inset) . The majority (60%) are missense; to know whether they are diseasecausing requires either expression analysis (see module in Fig. 1) , other knowledge about the evolutionary importance of the affected residues or careful analysis of the genotype-phenotype relationship in vivo. The other PAH mutations behave largely as nulls; nonsense (6%) and splice (13%) mutations together are a minority in this gene; deletions (13%), with five exceptions, are all small (<20 bp in length) and most produce frameshifts; the few insertions (1%) are also small, with frameshifts.
Genotype-phenotype correlations
A meta-analysis (13) of 365 probands harbouring 73 different PAH mutations in 161 different genotypes assigned mutations to 'severe', 'intermediate' and 'mild' classes by their effect on plasma phenylalanine homeostasis. The PAH genotype does not sufficiently explain the mutant phenotype in all cases implying that other factors are involved in the emergent property of homeostasis (13, 14) . A copy of the raw data set is stored in a compressed file on the PAHdb web site.
Expression analysis and molecular modelling
A module (co-edited by P.J.Waters) dedicated to expression analysis records 58 expression studies on 36 different human PAH mutations in seven different host systems (55% are in COS) using 10 different vectors (15) . Another module contains data on 22 different site-directed modifications of the rat gene (three corresponding to human alleles) and their effects on the rat enzyme (15) , which up to now has been its best studied species.
In a recent communication to PAHdb, R.C.Stevens (Berkeley, CA) mentions success with human PAH enzyme crystallization leading to a description of its 3D structure; in which case there is the possibility of molecular modelling in silico in parallel with the corresponding in vitro expression analysis.
Relative frequencies of PAH mutations
From 340 articles and 180 unpublished reports currently in the relevant module, we extracted data on relative frequencies of PAH mutations. Mutations (stratified by geographic region and population) are not shared on European and Oriental chromosomes (Fig. 3) , and only six different mutations account for 60% of the rare mutant haplotypes in the human population.
Polymorphic PAH haplotypes
The PAH locus is well endowed with known polymorphic markers (see Fig. 2 ); they include seven diallelic sites (RFLPs), two multiallelic markers (STR and VNTR), several silent SNPs in codons (e.g. Q232Q, V245V, L385L and Y414Y) and polymorphisms in the introns (e.g. IVS3nt-22c/t). From some of these markers, haplotypes are derived and associations with mutations analyzed.
Whereas the rare disease-producing PAH mutations are useful to study population histories (16) , their presence is necessary for such studies and not all human populations harbour these mutations at useful frequencies. Instead, and under appropriate conditions, the polymorphic PAH markers and haplotypes can be used for this purpose (17) .
Other features
The clinical page (http://www.mcgill.ca/pahdb/handout/ handout.htm) has wide acceptance and use. Students consult it; patients use it to gain information and pose questions (which the curators answer) and physicians use it for teaching. A mouse Pah gene page describes the mutagenized (ENU) mouse counterpart and orthologous phenotype (co-editor J.D.McDonald Wichita State University); the ENU mouse strains are powerful allies to study the physiology of PAH mutation effects and a new treatment option (18) . The cDNA sequence is annotated and all available information about intron sequences has been incorporated.
Visits and users
The Consortium Newsletter is distributed to 88 investigators in 28 countries. The counter on the website recorded 6431 visits over 429 days (up to September 11, 1997) from around the world (Fig. 4) ; 12% of visits originate from the .com domain; 10% from the .edu domain.
DISCUSSION
PAHdb is a relational database currently providing information on 328 different mutations at the PAH locus. A bias of ascertainment influences this record. First, the mutations were largely ascertained in probands with hyperphenylalaninemia; we do not know about the non-hyperphenylalaninemic population. Second, probands were largely ascertained in populations where newborn screening for hyperphenylalaninemia takes place as a public health practice; most Oriental and African populations, for example, are not screened. Accordingly the record of human PAH mutations is skewed.
PAHdb provides information that is both universal and relevant to the whole genome; and it is particular, being descriptive only of the PAH locus. The former is relevant to initiatives designed to survey the whole human genome. H.Lehvaslaiho (personal communication) lists eight fields that can be surveyed by SRS-based software in >20 different locus-specific mutation databases; they include species, genes, protein change, amino acid change, DNA change (both length, position and nucleotide) and mutation type. The locus-specific information is of interest to those attempting to relate a mutation to other features such as haplotype, phenotype, population structure and so on. The time has arrived to establish guidelines whereby genomic (central) databases and locus-specific databases can be linked to share information.
PAHdb has assigned unique identifiers (UIDs) to mutations. This practice has raised a problem yet to be resolved and requiring guidelines. Mutations on different chromosomes (alleles) may be identical-by-state but not necessarily identical by descent. For example, the R408W mutation (c.1222C→T) is identical-by-state on haplotypes 1.8 and 2.3 but not identical-by-descent because evidence indicates it is a recurrent mutation at a CpG site (11); the same is true for the E280K mutation (c.838G→A) on haplotypes 1.8 and 2.3 (19) . Accordingly, each of the R408W and E280K mutations on their separate haplotypes could eventually receive a different UID. On the other hand the G218V mutation, which occurs on haplotypes 1 and 7 by virtue of a single intragenic recombination (20) and is therefore identical by descent, would have only a single UID.
PAHdb, which documents mutation types, shows they may differ among genes. For example, PAH has few protein-truncation mutations compared with BRCA1 and few large deletions or insertions compared with LDLR. These differences reflect locusspecific features and will be informative about the fine structure of the human genome and the corresponding homologues in nonhuman species.
PAHdb documents relationships between genotypes and phenotypes. Accordingly, an interesting dimension of genetics, such as the function of a gene and parameters of related homeostasis, will emerge. This essential knowledge need not be lost in the mass of information emerging from the genome project and locus-specific mutation databases are one mechanism to retrieve and display it.
PAHdb contains intellectual property thus raising the issue of copyright. The data in our and other locus-specific mutation databases are freely shared with the broad community of scientists, educators, patients and others; the commercial sector is also a user of our database (Fig. 4) . The PAHdb home page advises users that information in the database is copyrighted intellectual property; users should cite the source of their information in the appropriate manner.
